{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:56:46Z","timestamp":1786982206112,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100009530","name":"Jawaharlal Institute Of Postgraduate Medical Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-022-01833-6","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T17:02:42Z","timestamp":1664470962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer"],"prefix":"10.1007","volume":"39","author":[{"given":"Thejeswar","family":"Nakka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxitaa","family":"Goenka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswajit","family":"Dubashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Kayal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanthi","family":"Mathaiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Barathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendran","family":"Krishnamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya Bala","family":"Thumaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhu","family":"Dahagama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2762-6591","authenticated-orcid":false,"given":"Prasanth","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"issue":"6","key":"1833_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12032-017-0960-z","volume":"34","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Med Oncol. 2017;34(6):103. https:\/\/doi.org\/10.1007\/s12032-017-0960-z.","journal-title":"Med Oncol"},{"issue":"27","key":"1833_CR2","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1200\/JCO.19.00194","volume":"37","author":"E Pujade-Lauraine","year":"2019","unstructured":"Pujade-Lauraine E, Banerjee S, Pignata S. Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives. J Clin Oncol. 2019;37(27):2437\u201348. https:\/\/doi.org\/10.1200\/JCO.19.00194.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1833_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/cancers11010119","volume":"11","author":"G Damia","year":"2019","unstructured":"Damia G, Broggini M. Platinum resistance in ovarian cancer: role of DNA repair. Cancers. 2019;11(1):119. https:\/\/doi.org\/10.3390\/cancers11010119.","journal-title":"Cancers"},{"key":"1833_CR4","doi-asserted-by":"crossref","unstructured":"Tapia G, Diaz-Padilla I. Molecular mechanisms of platinum resistance in ovarian cancer. Ovarian cancer\u2014a clinical and translational update. IntechOpen; 2013 [cited 2021 Sep 20]. https:\/\/www.intechopen.com\/chapters\/43348","DOI":"10.5772\/55562"},{"issue":"2","key":"1833_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.bbagen.2018.11.005","volume":"1863","author":"M Binju","year":"2019","unstructured":"Binju M, Padilla MA, Singomat T, Kaur P, Suryo Rahmanto Y, Cohen PA, et al. Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer\u2014a mini review. Biochim Biophys Acta Gen Subj. 2019;1863(2):371\u20138. https:\/\/doi.org\/10.1016\/j.bbagen.2018.11.005.","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"6","key":"1833_CR6","first-page":"2819","volume":"36","author":"E Cacan","year":"2016","unstructured":"Cacan E. Histone deacetylase-1-mediated suppression of FAS in chemoresistant ovarian cancer cells. Anticancer Res. 2016;36(6):2819\u201326.","journal-title":"Anticancer Res"},{"issue":"4","key":"1833_CR7","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1159\/000492260","volume":"48","author":"X Liu","year":"2018","unstructured":"Liu X, Yu Y, Zhang J, Lu C, Wang L, Liu P, et al. HDAC1 silencing in ovarian cancer enhances the chemotherapy response. Cell Physiol Biochem. 2018;48(4):1505\u201318. https:\/\/doi.org\/10.1159\/000492260.","journal-title":"Cell Physiol Biochem"},{"issue":"9","key":"1833_CR8","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1097\/IGC.0000000000000814","volume":"26","author":"P Kwieci\u0144ska","year":"2016","unstructured":"Kwieci\u0144ska P, Taub\u00f8ll E, Grzyb E, Fiedor E, Ptak A, Gregoraszczuk EL. Valproic acid as a promising co-treatment with paclitaxel and doxorubicin in different ovarian carcinoma cell lines. Int J Gynecol Cancer. 2016;26(9):1546\u201356. https:\/\/doi.org\/10.1097\/IGC.0000000000000814.","journal-title":"Int J Gynecol Cancer"},{"issue":"24","key":"1833_CR9","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M G\u00f6ttlicher","year":"2001","unstructured":"G\u00f6ttlicher M, Minucci S, Zhu P, Kr\u00e4mer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20(24):6969\u201378. https:\/\/doi.org\/10.1093\/emboj\/20.24.6969.","journal-title":"EMBO J"},{"issue":"5","key":"1833_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/01443615.2017.1290056","volume":"37","author":"Y Bozkaya","year":"2017","unstructured":"Bozkaya Y, Do\u011fan M, Umut Erdem G, Tulunay G, Uncu H, Ar\u0131k Z, et al. Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer. J Obstet Gynaecol. 2017;37(5):649\u201354. https:\/\/doi.org\/10.1080\/01443615.2017.1290056.","journal-title":"J Obstet Gynaecol"},{"issue":"18","key":"1833_CR11","doi-asserted-by":"publisher","first-page":"10029","DOI":"10.3390\/ijms221810029","volume":"22","author":"YM Shyu","year":"2021","unstructured":"Shyu YM, Liu LY, Chuang YJ. Synergistic effect of simultaneous versus sequential combined treatment of histone deacetylase inhibitor valproic acid with etoposide on melanoma cells. Int J Mol Sci. 2021;22(18):10029. https:\/\/doi.org\/10.3390\/ijms221810029.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1833_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/ijms19010164","volume":"19","author":"T Cerna","year":"2018","unstructured":"Cerna T, Hrabeta J, Eckschlager T, Frei E, Schmeiser HH, Arlt VM, et al. The histone deacetylase inhibitor valproic acid exerts a synergistic cytotoxicity with the DNA-damaging drug ellipticine in neuroblastoma cells. Int J Mol Sci. 2018;19(1):164. https:\/\/doi.org\/10.3390\/ijms19010164.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1833_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11060-007-9402-7","volume":"85","author":"CM Das","year":"2007","unstructured":"Das CM, Aguilera D, Vasquez H, Prasad P, Zhang M, Wolff JE, et al. Valproic acid induces p21 and topoisomerase-II (alpha\/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol. 2007;85(2):159\u201370. https:\/\/doi.org\/10.1007\/s11060-007-9402-7.","journal-title":"J Neurooncol"},{"issue":"12","key":"1833_CR14","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1182\/bloodadvances.2018019240","volume":"2","author":"K Drott","year":"2018","unstructured":"Drott K, Hagberg H, Papworth K, Relander T, Jerkeman M. Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID). Blood Adv. 2018;2(12):1386\u201392. https:\/\/doi.org\/10.1182\/bloodadvances.2018019240.","journal-title":"Blood Adv"},{"issue":"2","key":"1833_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJ Rustin","year":"2011","unstructured":"Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, Gynecological Cancer Intergroup, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 11 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419\u201323. https:\/\/doi.org\/10.1097\/IGC.0b013e3182070f17.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"1833_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1200\/JCO.1994.12.1.60","volume":"12","author":"PJ Hoskins","year":"1994","unstructured":"Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol. 1994;12(1):60\u20133. https:\/\/doi.org\/10.1200\/JCO.1994.12.1.60.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1833_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","volume":"16","author":"PG Rose","year":"1998","unstructured":"Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998;16(2):405\u201310. https:\/\/doi.org\/10.1200\/JCO.1998.16.2.405.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1833_CR18","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(18)30349-8","volume":"19","author":"CY Lan","year":"2018","unstructured":"Lan CY, Wang Y, Xiong Y, Li JD, Shen JX, Li YF, et al. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study. Lancet Oncol. 2018;19(9):1239\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(18)30349-8.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1833_CR19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ygyno.2021.05.025","volume":"162","author":"A Sharma","year":"2021","unstructured":"Sharma A, Singh M, Chauhan R, Malik PS, Khurana S, Mathur S, et al. Pazopanib based oral metronomic therapy for platinum resistant\/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial. Gynecol Oncol. 2021;162(2):382\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2021.05.025.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"1833_CR20","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1200\/JCO.2003.06.083","volume":"21","author":"MJ Edick","year":"2003","unstructured":"Edick MJ, Gajjar A, Mahmoud HH, van de Poll ME, Harrison PL, Panetta JC, et al. Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol. 2003;21(7):1340\u20136. https:\/\/doi.org\/10.1200\/JCO.2003.06.083.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1833_CR21","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.7314\/apjcp.2012.13.8.3977","volume":"13","author":"Z Shan","year":"2012","unstructured":"Shan Z, Feng-Nian R, Jie G, Ting Z. Effects of valproic acid on proliferation, apoptosis, angiogenesis and metastasis of ovarian cancer in vitro and in vivo. Asian Pac J Cancer Prev. 2012;13(8):3977\u201382. https:\/\/doi.org\/10.7314\/apjcp.2012.13.8.3977.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"1833_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2162-3619-4-4","volume":"26","author":"JK Damm","year":"2015","unstructured":"Damm JK, Gordon S, Ehinger M, Jerkeman M, Gullberg U, Hultquist A, et al. Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo. Exp Hematol Oncol. 2015;26(4):4. https:\/\/doi.org\/10.1186\/2162-3619-4-4.","journal-title":"Exp Hematol Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01833-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-022-01833-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01833-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T10:00:46Z","timestamp":1744192846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-022-01833-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1833"],"URL":"https:\/\/doi.org\/10.1007\/s12032-022-01833-6","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"assertion":[{"value":"19 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have any relevant conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"233"}}